(±)-4-methyl-1,2,4-pentanetriol | 871888-50-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (±)-4-methyl-1,2,4-pentanetriol
• 英文别名: 4-methylpentane-1,2,4-triol；4-Methyl-pentan-1,2,4-triol；β.δ.ε-Trioxy-β-methyl-pentan；4-Methyl-1,2,4-pentanetriol
• CAS: 871888-50-5
• 化学式: C₆H₁₄O₃
• 分子量: 134.175
• InChiKey: GESPJGVSMTZOBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (±)-4-methyl-1,2,4-pentanetriol 在 permanganate(VII) ion 作用下， 生成 β-羟基异戊酸
  参考文献：
  名称：

  Reformatski, Journal fur praktische Chemie (Leipzig 1954), 1889, vol. <2> 40, p. 412

  摘要：

  DOI：
• 作为产物：
  描述：

  2-甲-4-戊烯-2-醇 在 (DHQD)2PHAL 作用下， 以 水 、 叔丁醇 为溶剂， 反应 72.0h， 生成 (±)-4-methyl-1,2,4-pentanetriol
  参考文献：
  名称：

  [EN] COMPOUNDS USEFUL AS KINASE INHIBITORS
  [FR] COMPOSÉS UTILISÉS COMME INHIBITEURS DE KINASE

  摘要：

  这项发明涉及新颖的化合物。该发明的化合物是酪氨酸激酶抑制剂。具体来说，该发明的化合物可用作布鲁顿氏酪氨酸激酶（BTK）的抑制剂。该发明还考虑了利用这些化合物治疗通过抑制布鲁顿氏酪氨酸激酶可治疗的疾病，例如癌症、淋巴瘤、白血病和免疫性疾病。

  公开号：

  WO2017103611A1

文献信息

• [EN] A TOPICAL COMPOSITION CONTAINING A VITAMIN D DERIVATIVE<br/>[FR] COMPOSITION TOPIQUE CONTENANT UN DERIVE DE VITAMINE D
  申请人：UNIV BEN GURION

  公开号：WO2005105071A1

  公开（公告）日：2005-11-10

  The invention provides a topical composition comprising a conjugate of a vitamin D derivatiave and a fatty acid.

  这项发明提供了一种含有维生素D衍生物和脂肪酸的局部组合物。
• Polyester/Polyamide blend having improved flavor retaining property and clarity
  申请人：EASTMAN CHEMICAL COMPANY

  公开号：EP0969047A2

  公开（公告）日：2000-01-05

  This invention relates to a polyester/polyamide blend having an excellent gas barrier property and an improved flavor retaining property and clarity. More particularly, the present invention relates to a polyethylene terephthalate/low molecular weight polyamide blend having an excellent gas barrier property, in which by reducing the concentration of acetaldehyde contained in the polyester, the storage property of a food or the like and the flavor-retaining property and fragrance retaining property are highly improved without producing haze.

  本发明涉及一种聚酯/聚酰胺混合物，该混合物具有优异的气体阻隔性能，并改善了风味保持性能和透明度。更具体地说，本发明涉及一种具有优异气体阻隔性的聚对苯二甲酸乙二醇酯/低分子量聚酰胺混合物，通过降低聚酯中所含乙醛的浓度，可高度改善食品或类似物的贮存性能以及风味保持性能和香味保持性能，且不会产生雾度。
• Concentrated, stable, fabric softening composition
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP1352948A1

  公开（公告）日：2003-10-15

  Principal solvents, especially mono-ol and diol principal solvents, having a ClogP of from about 0.15 to about 0.64, preferably from about 0.25 to about 0.62, and more preferably from about 0.40 to about 0.60, are disclosed that have the ability to make clear aqueous fabric softener compositions containing relatively high concentrations of fabric softener actives having ester linkages in their long, hydrophobic chains. The fabric softener actives are either unsaturated, or have intermediate length chains (∼C12-14) and the said principal solvents are used at levels of less than about 40%. Other solvents may be present. Some of the said principal solvents are novel compounds and/or novel mixtures. Premixes of the fabric softening actives, the principal solvents, and, optionally, other solvents are useful in the preparation of complete formulations by obviating/limiting the need for heating.

  本发明公开了主溶剂，特别是单醇和二醇主溶剂，其 ClogP 值约为 0.15 至 0.64，优选约为 0.25 至 0.62，更优选约为 0.40 至 0.60，这些主溶剂能够制成透明的水性织物柔软剂组合物，其中含有相对高浓度的织物柔软剂活性成分，这些活性成分的疏水长链中具有酯连接。织物柔软剂活性成分要么是不饱和的，要么具有中间长度的链（∼C12-14），上述主要溶剂的使用量低于约 40%。也可以使用其他溶剂。其中一些主溶剂是新型化合物和/或新型混合物。织物软化活性剂、主溶剂和其他溶剂的预混物可避免/限制加热的需要，从而有助于制备完整的配方。
• Compounds useful as kinase inhibitors
  申请人：Loxo Oncology, Inc.

  公开号：US10342780B2

  公开（公告）日：2019-07-09

  This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

  本发明涉及新型化合物。本发明的化合物是酪氨酸激酶抑制剂。具体来说，本发明的化合物可用作布鲁顿酪氨酸激酶（BTK）的抑制剂。本发明还考虑将这些化合物用于治疗可通过抑制布鲁顿酪氨酸激酶治疗的疾病，例如癌症、淋巴瘤、白血病和免疫性疾病。
• Sodium hyaluronate microspheres
  申请人：Clear Solutions Biotech, Inc.

  公开号：US20030096734A1

  公开（公告）日：2003-05-22

  The present invention relates to microspheres comprising hyaluronan derivatized with a bifunctional crosslinker to form microspheres. Methods of making such microspheres, comprising mixing hyaluronic acid and a dihydrazide with a crosslinker in an aqueous solution, adding a solvent and an emulsifying agent to form an emulsion, and lowering the pH of the emulsion to allow intramolecular and intermolecular crosslinking to occur, are also disclosed. The invention also provides for pharmaceutical or cosmetic formulations based on the microspheres described herein, further containing one or more active or cosmetic agents, and methods of using such formulations.

  本发明涉及由用双官能团交联剂衍生形成微球的透明质酸组成的微球。本发明还公开了制造这种微球的方法，包括在水溶液中将透明质酸和二酰肼与交联剂混合，加入溶剂和乳化剂以形成乳液，并降低乳液的 pH 值以发生分子内和分子间交联。本发明还提供了基于本文所述微球的药物或化妆品制剂，进一步含有一种或多种活性剂或化妆品剂，以及使用这种制剂的方法。